MultiplexDX, s.r.o.

MultiplexDX is one of the most innovative biotech corporations, created to bring itsrevolutionary technologies to the market of personalized molecular diagnostics. The companyhas representation in both U.S. and European markets. The collaborators of MultiplexDX arefrom the world’s most prestigious scientifi c organizations including the National CancerInstitute (MD, USA), Rockefeller University (NY, USA), Memorial Sloan Kettering Cancer Center(NY, USA), Queens University (Kingston, Ontario, Canada), University of Warsaw (Poland), andTechnical University of Dresden (Germany).

MultiplexDX’s innovative platform merges histopathology, multiplexed spatial analysis ofbiomarkers, and laser capture microdissection RNA sequencing into one diagnostic test. Thismultimodal, cross-validated approach mitigates diagnostic errors, unveils tumor heterogeneity,and provides precise and accurate cancer profi ling for each patient, which allows clinicians tosuggest a specifi c, personalized cancer treatment.

MultiplexDX innovative portfolio covers COVID-19 diagnostics; custom oligonucleotides; RNASequenc-ing; RNA FISH; Bioinformatics and Personalized Diagnostics.

Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter.